The National Hemophilia Foundation’s (NHF) Medical and Scientific Advisory Council (MASAC) has issued the following updated document, which was adopted by NHF’s Board of Directors on June 13, 2013:
MASAC Document #217: MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders (Revised April 2013)
The document includes:
- Recommendations for physicians treating patients with hemophilia A and B, von Willebrand disease and other congenital bleeding disorders
- Recommendations to manufacturers of coagulation products
- Recommendations to the Food and Drug Administration
To view this document, click the link above or review the complete list of current MASAC documents. To request a hard copy of any current documents, please contact HANDI, NHF’s information resource center: handi@hemophilia.org or 1.800.424.2634
